Mesoblast Up 25% After Hours on Collaboration With Novartis
By Josh Beckerman
Mesoblast Ltd. American depositary receipts surged 25% to $14.70 after hours as the corporate entered an unique worldwide license and collaboration settlement with Novartis AG for Mesoblast’s mesenchymal stromal cell product remestemcel-L.
The preliminary focus might be on remedy of acute respiratory misery syndrome, together with that related to Covid-19.
Write to Josh Beckerman at [email protected]
(END) Dow Jones Newswires
November 19, 2020 17:38 ET (22:38 GMT)
Copyright (c) 2020 Dow Jones & Firm, Inc.
Market information on CNN.
Dow Jones – Mesoblast Up 25% After Hours on Collaboration With Novartis